DK3037424T3 - NEW QUINOLIN-SUBSTITUTED COMPOUND - Google Patents
NEW QUINOLIN-SUBSTITUTED COMPOUND Download PDFInfo
- Publication number
- DK3037424T3 DK3037424T3 DK14837210.5T DK14837210T DK3037424T3 DK 3037424 T3 DK3037424 T3 DK 3037424T3 DK 14837210 T DK14837210 T DK 14837210T DK 3037424 T3 DK3037424 T3 DK 3037424T3
- Authority
- DK
- Denmark
- Prior art keywords
- amino
- quinolin
- compound
- methylene
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 10
- -1 pyrrolizin-7-yl Chemical group 0.000 claims 9
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002817 1-piperidinomethyl group Chemical group [H]C([H])([*])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- MKCYPWYURWOKST-INIZCTEOSA-N NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 MKCYPWYURWOKST-INIZCTEOSA-N 0.000 claims 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 3
- XGSYUTSLKZLTRT-FYCOFBDGSA-N (e)-n-[(7s)-4-amino-6-methylidene-5-quinolin-3-yl-7,8-dihydropyrimido[5,4-b]pyrrolizin-7-yl]-3-chloroprop-2-enamide Chemical compound C1=CC=CC2=CC(C3=C4C(=C)[C@H](NC(=O)\C=C\Cl)CN4C=4N=CN=C(C3=4)N)=CN=C21 XGSYUTSLKZLTRT-FYCOFBDGSA-N 0.000 claims 2
- YYVXXGWLFNYTLN-ZTWVHDNBSA-N NC1=NC=NC2=C1C(=C1/C(/C[C@@H](CN21)NC(C=C)=O)=C/C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1/C(/C[C@@H](CN21)NC(C=C)=O)=C/C)C=1C=NC2=CC=CC=C2C=1 YYVXXGWLFNYTLN-ZTWVHDNBSA-N 0.000 claims 2
- FQJFMMQDDNXOFM-QGZVFWFLSA-N NC1=NC=NC2=C1C(=C1C(=C[C@H](CN21)N(C(C=C)=O)C)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(=C[C@H](CN21)N(C(C=C)=O)C)C)C=1C=NC2=CC=CC=C2C=1 FQJFMMQDDNXOFM-QGZVFWFLSA-N 0.000 claims 2
- HBVFTJZAUKPAOD-INIZCTEOSA-N NC1=NC=NC2=C1C(=C1C(C[C@@H](CN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(C[C@@H](CN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 HBVFTJZAUKPAOD-INIZCTEOSA-N 0.000 claims 2
- ARPLOLYRIWWVOR-QGZVFWFLSA-N NC1=NC=NC2=C1C(=C1C(C[C@H](CN21)N(C(C=C)=O)C)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(C[C@H](CN21)N(C(C=C)=O)C)=C)C=1C=NC2=CC=CC=C2C=1 ARPLOLYRIWWVOR-QGZVFWFLSA-N 0.000 claims 2
- XGSYUTSLKZLTRT-MWWKQMNYSA-N NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(\C=C/Cl)=O)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(\C=C/Cl)=O)=C)C=1C=NC2=CC=CC=C2C=1 XGSYUTSLKZLTRT-MWWKQMNYSA-N 0.000 claims 2
- AABPHMBNZZDIHO-KRWDZBQOSA-N NC1=NC=NC2=C1C(=C1C([C@H](CN21)N(C(C=C)=O)C)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@H](CN21)N(C(C=C)=O)C)=C)C=1C=NC2=CC=CC=C2C=1 AABPHMBNZZDIHO-KRWDZBQOSA-N 0.000 claims 2
- BBTMYZZONHFZFE-QGZVFWFLSA-N N-[(7S)-4-amino-6-methylidene-5-quinolin-3-yl-7,8-dihydropyrimido[5,4-b]pyrrolizin-7-yl]but-2-enamide Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C=CC)=O)=C)C=1C=NC2=CC=CC=C2C=1 BBTMYZZONHFZFE-QGZVFWFLSA-N 0.000 claims 1
- XGPLSBMXOCDBDO-QGZVFWFLSA-N N-[(7S)-4-amino-6-methylidene-5-quinolin-3-yl-7,8-dihydropyrimido[5,4-b]pyrrolizin-7-yl]but-2-ynamide Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C#CC)=O)=C)C=1C=NC2=CC=CC=C2C=1 XGPLSBMXOCDBDO-QGZVFWFLSA-N 0.000 claims 1
- MKCYPWYURWOKST-MRXNPFEDSA-N NC1=NC=NC2=C1C(=C1C(=C[C@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(=C[C@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 MKCYPWYURWOKST-MRXNPFEDSA-N 0.000 claims 1
- HBVFTJZAUKPAOD-MRXNPFEDSA-N NC1=NC=NC2=C1C(=C1C(C[C@H](CN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(C[C@H](CN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 HBVFTJZAUKPAOD-MRXNPFEDSA-N 0.000 claims 1
- PNBVXUUHQRNXEH-MRXNPFEDSA-N NC1=NC=NC2=C1C(=C1C([C@@H](CCN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CCN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 PNBVXUUHQRNXEH-MRXNPFEDSA-N 0.000 claims 1
- AABPHMBNZZDIHO-QGZVFWFLSA-N NC1=NC=NC2=C1C(=C1C([C@@H](CN21)N(C(C=C)=O)C)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CN21)N(C(C=C)=O)C)=C)C=1C=NC2=CC=CC=C2C=1 AABPHMBNZZDIHO-QGZVFWFLSA-N 0.000 claims 1
- RLMXXZGDSAUHHX-MRXNPFEDSA-N NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C#C)=O)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C#C)=O)=C)C=1C=NC2=CC=CC=C2C=1 RLMXXZGDSAUHHX-MRXNPFEDSA-N 0.000 claims 1
- OQNFSNAPCNWXFE-QGZVFWFLSA-N NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C(=C)C)=O)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C(=C)C)=O)=C)C=1C=NC2=CC=CC=C2C=1 OQNFSNAPCNWXFE-QGZVFWFLSA-N 0.000 claims 1
- NYZLBECBOHTDFP-MRXNPFEDSA-N NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 NYZLBECBOHTDFP-MRXNPFEDSA-N 0.000 claims 1
- GXMBFEMPGWKDHV-PVQCJRHBSA-N NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 GXMBFEMPGWKDHV-PVQCJRHBSA-N 0.000 claims 1
- QFWKCLYABFSKKQ-MBNRZODZSA-N NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(\C=C\CN(C)C)=O)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@@H](CN21)NC(\C=C\CN(C)C)=O)=C)C=1C=NC2=CC=CC=C2C=1 QFWKCLYABFSKKQ-MBNRZODZSA-N 0.000 claims 1
- NYZLBECBOHTDFP-INIZCTEOSA-N NC1=NC=NC2=C1C(=C1C([C@H](CN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C([C@H](CN21)NC(C=C)=O)=C)C=1C=NC2=CC=CC=C2C=1 NYZLBECBOHTDFP-INIZCTEOSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013172746 | 2013-08-22 | ||
| PCT/JP2014/071951 WO2015025936A1 (ja) | 2013-08-22 | 2014-08-22 | 新規キノリン置換化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3037424T3 true DK3037424T3 (en) | 2017-12-11 |
Family
ID=52483707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14837210.5T DK3037424T3 (en) | 2013-08-22 | 2014-08-22 | NEW QUINOLIN-SUBSTITUTED COMPOUND |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9650386B2 (enExample) |
| EP (1) | EP3037424B1 (enExample) |
| JP (1) | JP6161705B2 (enExample) |
| KR (1) | KR101906688B1 (enExample) |
| CN (1) | CN105683195B (enExample) |
| AU (1) | AU2014309788B2 (enExample) |
| BR (1) | BR112016003247B1 (enExample) |
| CA (1) | CA2922077C (enExample) |
| DK (1) | DK3037424T3 (enExample) |
| ES (1) | ES2656712T3 (enExample) |
| HU (1) | HUE034807T2 (enExample) |
| MX (1) | MX370808B (enExample) |
| MY (1) | MY182891A (enExample) |
| NO (1) | NO3037424T3 (enExample) |
| PH (1) | PH12016500225A1 (enExample) |
| PL (1) | PL3037424T3 (enExample) |
| PT (1) | PT3037424T (enExample) |
| RU (1) | RU2689158C2 (enExample) |
| SG (1) | SG11201600759XA (enExample) |
| TW (1) | TWI603971B (enExample) |
| WO (1) | WO2015025936A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016003247B1 (pt) * | 2013-08-22 | 2022-05-10 | Taiho Pharmaceutical Co., Ltd | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso |
| JOP20190073A1 (ar) * | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| EP3541832A4 (en) * | 2016-11-17 | 2020-09-30 | Board of Regents, The University of Texas System | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS CARRIER OF EGFR OR HER2 MUTATIONS EXON 20 |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| FR3068971B1 (fr) * | 2017-07-12 | 2019-08-30 | Protneteomix | Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer |
| ES2972895T3 (es) | 2017-09-01 | 2024-06-17 | Taiho Pharmaceutical Co Ltd | Inhibidor selectivo del EGFR mutante en el exón 18 y/o en el exón 21 |
| TWI837266B (zh) * | 2018-12-28 | 2024-04-01 | 日商大鵬藥品工業股份有限公司 | L718及/或l792突變型治療抗性egfr抑制劑 |
| SG11202110376XA (en) | 2019-03-19 | 2021-10-28 | Voronoi Inc | Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| WO2021057796A1 (zh) * | 2019-09-29 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| WO2022007841A1 (zh) * | 2020-07-09 | 2022-01-13 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2022265950A1 (en) | 2021-06-15 | 2022-12-22 | Genentech, Inc. | Egfr inhibitor and perk activator in combination therapy and their use for treating cancer |
| CN115707704B (zh) * | 2021-08-20 | 2024-09-13 | 广东医诺维申生物技术有限公司 | 氘代稠合三环类化合物及其组合物和用途 |
| EP4630120A1 (en) * | 2022-12-08 | 2025-10-15 | Assia Chemical Industries Ltd. | Solid state forms of zipalertinib and process for preparation thereof |
| CN115785107B (zh) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
| TW202502767A (zh) * | 2023-05-31 | 2025-01-16 | 日商大鵬藥品工業股份有限公司 | 喹啉取代化合物之結晶 |
| WO2025141465A1 (en) | 2023-12-27 | 2025-07-03 | Assia Chemical Industries Ltd. | Solid state forms of zipalertinib hydrochloride and process for preparation thereof |
| WO2025167588A1 (zh) * | 2024-02-05 | 2025-08-14 | 苏州科睿思制药有限公司 | Zipalertinib的晶型及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) * | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| WO2006102079A1 (en) | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| PL2452940T3 (pl) * | 2009-07-10 | 2015-05-29 | Taiho Pharmaceutical Co Ltd | Związek azabicykliczny i jego sól |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| RU2013136895A (ru) * | 2011-01-07 | 2015-02-20 | Тайхо Фармасьютикал Ко., Лтд. | Новое бициклическое соединение или его соль |
| WO2013047813A1 (ja) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| US8889666B2 (en) | 2012-02-23 | 2014-11-18 | Taiho Pharmaceutical Co., Ltd. | Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof |
| US9845329B2 (en) * | 2013-02-22 | 2017-12-19 | Taiho Pharmaceutical Co., Ltd. | Method for producing a substituted 6,7,8,9-tetrahydropyrimido[5,4-b]indolizine, substituted 7,8,9,10-tetrahydro-6H-pyrimido[5′,4′:4,5]pyrrolo[1,2-a]azepine and substituted 6,7,8,9,10,11-hexahydropyrimido[5′,4′:4,5]pyrrolo[1,2-a]azocine |
| BR112016003247B1 (pt) * | 2013-08-22 | 2022-05-10 | Taiho Pharmaceutical Co., Ltd | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso |
-
2014
- 2014-08-22 BR BR112016003247-0A patent/BR112016003247B1/pt active IP Right Grant
- 2014-08-22 AU AU2014309788A patent/AU2014309788B2/en active Active
- 2014-08-22 US US14/911,093 patent/US9650386B2/en active Active
- 2014-08-22 MY MYPI2016700465A patent/MY182891A/en unknown
- 2014-08-22 NO NO14837210A patent/NO3037424T3/no unknown
- 2014-08-22 ES ES14837210.5T patent/ES2656712T3/es active Active
- 2014-08-22 CN CN201480058192.XA patent/CN105683195B/zh active Active
- 2014-08-22 SG SG11201600759XA patent/SG11201600759XA/en unknown
- 2014-08-22 KR KR1020167007071A patent/KR101906688B1/ko active Active
- 2014-08-22 WO PCT/JP2014/071951 patent/WO2015025936A1/ja not_active Ceased
- 2014-08-22 DK DK14837210.5T patent/DK3037424T3/en active
- 2014-08-22 RU RU2016110096A patent/RU2689158C2/ru active
- 2014-08-22 PT PT148372105T patent/PT3037424T/pt unknown
- 2014-08-22 EP EP14837210.5A patent/EP3037424B1/en active Active
- 2014-08-22 HU HUE14837210A patent/HUE034807T2/en unknown
- 2014-08-22 TW TW103129036A patent/TWI603971B/zh active
- 2014-08-22 CA CA2922077A patent/CA2922077C/en active Active
- 2014-08-22 JP JP2015532903A patent/JP6161705B2/ja active Active
- 2014-08-22 PL PL14837210T patent/PL3037424T3/pl unknown
- 2014-08-22 MX MX2016002125A patent/MX370808B/es active IP Right Grant
-
2016
- 2016-02-02 PH PH12016500225A patent/PH12016500225A1/en unknown
- 2016-12-19 US US15/382,883 patent/US9758526B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3037424T3 (en) | NEW QUINOLIN-SUBSTITUTED COMPOUND | |
| CN104903321B (zh) | 作为激酶抑制剂的经取代三环苯并咪唑 | |
| KR101828187B1 (ko) | 신규 축합 피리미딘 화합물 또는 그 염 | |
| DK2722332T3 (en) | Quinolylpyrrolopyrimidylforbindelse with concentrated ring or salt thereof. | |
| WO2013118817A1 (ja) | キノリルピロロピリミジン化合物又はその塩 | |
| KR20190021345A (ko) | Egfr 저해제로 제공되는 아닐린 피리미딘 화합물의 결정 | |
| RU2797117C2 (ru) | Новое хинолин-замещенное соединение | |
| HK1222393B (en) | Quinoline-substituted compound |